Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Exagen (XGN) EBITDA (2018 - 2025)

Historic EBITDA for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to -$3.1 million.

  • Exagen's EBITDA rose 3351.92% to -$3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.5 million, marking a year-over-year increase of 1897.4%. This contributed to the annual value of -$13.6 million for FY2024, which is 4028.99% up from last year.
  • Exagen's EBITDA amounted to -$3.1 million in Q3 2025, which was up 3351.92% from -$2.6 million recorded in Q2 2025.
  • Over the past 5 years, Exagen's EBITDA peaked at -$2.6 million during Q2 2024, and registered a low of -$14.5 million during Q4 2022.
  • For the 5-year period, Exagen's EBITDA averaged around -$6.1 million, with its median value being -$5.1 million (2023).
  • As far as peak fluctuations go, Exagen's EBITDA tumbled by 14493.21% in 2022, and later soared by 6505.26% in 2023.
  • Exagen's EBITDA (Quarter) stood at -$6.3 million in 2021, then plummeted by 131.71% to -$14.5 million in 2022, then skyrocketed by 64.48% to -$5.1 million in 2023, then soared by 34.27% to -$3.4 million in 2024, then increased by 8.37% to -$3.1 million in 2025.
  • Its EBITDA stands at -$3.1 million for Q3 2025, versus -$2.6 million for Q2 2025 and -$3.4 million for Q1 2025.